MedTrace Logo

VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

NCT07254481 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2025-11-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.

Conditions

Interventions

DRUG

VB19055

In this part, VB19055 tablets will be administered as a single or multiple oral dose.

DRUG

VB19055 placebo

In this part, VB19055 placebo tablets will be administered as a single or multiple oral dose.

Sponsors & Collaborators

  • Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiguang Wang · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-05
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07254481 on ClinicalTrials.gov